iPSC-Derived Microglia

iPSC-Derived Microglia

Overview

iPSC-derived microglia are microglia cells generated from induced pluripotent stem cells (iPSCs) through directed differentiation protocols. These cells represent a major advancement in neurodegeneration research by providing a renewable, patient-specific source of microglia—the primary immune cells of the central nervous system. Unlike traditional immortalized cell lines or primary microglia isolated from post-mortem tissue, iPSC-derived microglia maintain many functional characteristics of native microglia while offering the practical advantages of scalability, standardization, and genetic accessibility. They have become an essential tool for modeling neuroinflammatory aspects of neurodegenerative diseases in vitro.

Function/Biology

iPSC-derived microglia are generated through sequential differentiation protocols that recapitulate the developmental pathway of microglial specification. Most protocols begin with iPSCs, differentiate them into embryoid bodies or hematopoietic progenitor cells, and then guide specification toward a microglial lineage through exposure to specific growth factors including macrophage colony-stimulating factor (M-CSF), interleukin-3 (IL-3), and fetal liver tyrosine kinase 3 ligand (FLT3L). The resulting cells express canonical microglial markers including IBA1 (ionized calcium-binding adapter molecule 1), CD11b, and CX3CR1.

iPSC-Derived Microglia

Overview

iPSC-derived microglia are microglia cells generated from induced pluripotent stem cells (iPSCs) through directed differentiation protocols. These cells represent a major advancement in neurodegeneration research by providing a renewable, patient-specific source of microglia—the primary immune cells of the central nervous system. Unlike traditional immortalized cell lines or primary microglia isolated from post-mortem tissue, iPSC-derived microglia maintain many functional characteristics of native microglia while offering the practical advantages of scalability, standardization, and genetic accessibility. They have become an essential tool for modeling neuroinflammatory aspects of neurodegenerative diseases in vitro.

Function/Biology

iPSC-derived microglia are generated through sequential differentiation protocols that recapitulate the developmental pathway of microglial specification. Most protocols begin with iPSCs, differentiate them into embryoid bodies or hematopoietic progenitor cells, and then guide specification toward a microglial lineage through exposure to specific growth factors including macrophage colony-stimulating factor (M-CSF), interleukin-3 (IL-3), and fetal liver tyrosine kinase 3 ligand (FLT3L). The resulting cells express canonical microglial markers including IBA1 (ionized calcium-binding adapter molecule 1), CD11b, and CX3CR1.

Functionally, iPSC-derived microglia exhibit core microglial behaviors including phagocytosis, cytokine production, chemotactic migration, and morphological responsiveness to stimuli. They can engulf pathological proteins, cellular debris, and apoptotic neurons—functions critical to maintaining neural tissue homeostasis. When activated by inflammatory signals such as lipopolysaccharide (LPS) or interferon-gamma (IFN-γ), these cells produce pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). They also express toll-like receptors (TLRs) and other pattern recognition receptors that enable pathogen and danger-associated molecular pattern (PAMP/DAMP) detection.

Role in Neurodegeneration

Microglia are increasingly recognized as central players in neurodegenerative disease pathogenesis. iPSC-derived microglia provide a platform to investigate whether microglial dysfunction contributes to disease or represents a response to neuronal damage. In Alzheimer's disease research, iPSC-derived microglia from patients can be co-cultured with neurons expressing familial Alzheimer's disease (fAD) mutations or exposed to amyloid-beta, allowing characterization of disease-specific microglial responses. Similarly, in Parkinson's disease, patient-derived microglia can be studied for their responses to alpha-synuclein pathology. These models have revealed that patient microglia sometimes exhibit exaggerated inflammatory responses or impaired phagocytic clearance of pathological proteins, supporting the hypothesis that microglial dysfunction contributes to neurodegeneration.

Molecular Mechanisms

iPSC-derived microglia exhibit disease-associated molecular changes in neurodegenerative models. Key mechanisms under investigation include altered TREM2 (triggering receptor expressed on myeloid cells 2) signaling, which affects phagocytic capacity; dysregulated NF-κB pathway activation, driving pro-inflammatory gene expression; impaired autophagy, reducing clearance of intracellular pathogens and protein aggregates; and altered lipid metabolism, which influences microglial polarization and function. Disease-associated microglia (DAM) signatures—characterized by upregulation of genes like APOE, ITGAX, and CLEC7A—have been documented in iPSC-derived microglia modeling neurodegeneration.

Clinical/Research Significance

iPSC-derived microglia enable disease modeling at scale and facilitate high-throughput screening for compounds that modulate microglial function. They allow generation of genetically matched controls and disease variants from the same patient background, reducing genetic confounding variables. These cells have proven valuable for understanding inherited forms of neurodegeneration, including how specific TREM2 mutations affect microglial responses. Additionally, iPSC-derived microglia can be differentiated from patients with sporadic neurodegeneration, potentially identifying microglial biomarkers or phenotypes associated with disease susceptibility.

Related Entities

• Microglia: Native microglial cells and their developmental biology
• Induced Pluripotent Stem Cells (iPSCs): Foundational technology for generating iPSC-derived microglia
• Neuroinflammation: Broader field addressing immune mechanisms in neurodegeneration
• Phagocytosis: Microglial clearance function central to neurodegeneration
• TREM2: Key receptor pathway in microglial biology and neurodegeneration
• Alzheimer's disease, Parkinson's disease: Primary disease models utilizing iPSC-derived microglia
• Neuronal-glial co-culture systems: Integration of iPSC-derived microglia with neurons for disease modeling